Patent Assignment
Reel/Frame 070636/0331
Patent Transfer Agreement
Recorded: 2025-03-26
Pages: 13
Assignor
QIAGEN NORTH AMERICAN HOLDINGS, INC.
Executed: 2025-01-10
Assignee
QIAGEN SCIENCES LLC
19300 GERMANTOWN ROAD, GERMANTOWN, MARYLAND, 20874
Covered Properties
(18)
Cell-Mediated Immune Response Assay and Kits Therefor
Assay for Measuring Cell-Mediated Immunoresponsiveness
Diagnostic Assay
Use of Amino Acid Sequences from Mycobacterium Tuberculosis or Corresponding Nucleic Acids for Diagnosis and Prevention of Tubercular Infection, Diagnostic Kit and Vaccine Therefrom
Tlr Agonist-Enhanced in Vitro Assay of Cell Mediated Immune Responsiveness
Cell Mediated Immune Response Assay with Enhanced Sensitivity
Cell Mediated Immune Response Assay
Use of Amino Acid Sequences from Mycobacterium Tuberculosis or Corresponding Nucleic Acids for Diagnosis and Prevention of Tubercular Infection, Diagnostic Kit and Vaccine Therefrom
Use of Amino Acid Sequences from Mycobacterium Tuberculosis or Corresponding Nucleic Acids for Diagnosis and Prevention of Tubercular Infection, Diagnostic Kit and Vaccine Therefrom
Use of Amino Acid Sequences from Mycobacterium Tuberculosis or Corresponding Nucleic Acids for Diagnosis and Prevention of Tubercular Infection, Diagnostic Kit and Vaccine Therefrom
Tlr Agonist-Enhanced in Vitro Assay of Cell Mediated Immune Responsiveness
Cell Mediated Immune Response Assay
Use of Amino Acid Sequences from Mycobacterium Tuberculosis or Corresponding Nucleic Acids for Diagnosis and Prevention of Tubercular Infection, Diagnostic Kit and Vaccine Therefrom
Use of Amino Acid Sequences from Mycobacterium Tuberculosis or Corresponding Nucleic Acids for Diagnosis and Prevention of Tubercular Infection, Diagnostic Kit and Vaccine Therefrom
Cell Mediated Immune Response Assay
Application:
18/917,106 →
Use of Amino Acid Sequences from Mycobacterium Tuberculosis or Corresponding Nucleic Acids for Diagnosis and Prevention of Tubercular Infection, Diagnostic Kit and Vaccine Therefrom
Application:
18/951,781 →
Publication:
US 2025/0093352
Cell Mediated Immune Response Assay
Application:
19/016,630 →
Publication:
US 2025/0369957
Cell Mediated Immune Response Assay with Enhanced Sensitivity
Application:
19/019,927 →
Publication:
US 2025/0369968
Related Assignments
(10)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Dec 4, 2009
From: RADFORD, ANTHONY J.; JONES, STEPHEN L.; HOWARD, JENNY L.
To: CELLESTIS LIMITED
Reel/Frame 023605/0284 →
Assignment of Assignor's Interest
Aug 21, 2012
From: BOYLE, JEFF; DE LAS HERAS, RACHEL
To: CELLESTIS LIMITED
Reel/Frame 028822/0755 →
Assignment of Assignor's Interest
Jun 5, 2013
From: MARIANI, FRANCESCA; AMICOSANTE, MASSIMO; COLIZZI, VITTORIO; SALTINI, CESARE
To: CELLESTIS LIMITED
Reel/Frame 030553/0502 →
Assignment of Assignor's Interest
Jul 16, 2013
From: RADFORD, ANTHONY J.; MANKTELOW, EMILY; BOYLE, JEFF; HOWARD, JENNY LOUISE
To: CELLESTIS INTERNATIONAL PTY LTD.
Reel/Frame 030810/0874 →
Assignment of Assignor's Interest
Feb 25, 2014
From: BOYLE, JEFF; MANKTELOW, EMILY
To: CELLESTIS LIMITED
Reel/Frame 032291/0639 →
Assignment of Assignor's Interest
Apr 18, 2014
From: BOYLE, JEFF
To: CELLESTIS LIMITED
Reel/Frame 032708/0909 →
Assignment of Assignor's Interest
Nov 10, 2015
From: BOYLE, JEFF; KNIGHTS, ASHLEY; MUNIAN, CARMEN
To: CELLESTIS LIMITED
Reel/Frame 037002/0726 →
Assignment of Assignor's Interest
Mar 21, 2025
From: CELLESTIS PTY. LTD.
To: QIAGEN AUSTRALIA HOLDING PTY LTD.
Reel/Frame 070587/0530 →
Change of Name
Mar 21, 2025
From: CELLESTIS LIMITED
To: CELLESTIS PTY LTD
Reel/Frame 070588/0275 →
Resolution of Joint and Several Liquiditators
Mar 25, 2025
From: QIAGEN AUSTRALIA HOLDING PTY LTD
To: QIAGEN NORTH AMERICAN HOLDINGS INC.
Reel/Frame 070619/0276 →